您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > TRC160334
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
TRC160334
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
TRC160334图片
规格:98%
分子量:337.35
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议

产品介绍
TRC160334 是缺氧诱导因子 (HIF) 羟化酶抑制剂。TRC160334 可用于研究缺血/再灌注损伤。
货号:ajcx36776
CAS:1293289-69-6
分子式:C14H15N3O5S
分子量:337.35
溶解度:DMSO : 50 mg/mL (148.21 mM; ultrasonic and warming and heat to 60°C)
纯度:98%
存储:Store at -20°C
库存:现货

Background:

TRC160334 is a hypoxia-inducible factor (HIF) hydroxylase inhibitor. TRC160334 can be used for the research of ischemia/reperfusion injury[1].

TRC160334 (100~400 μμ; 4 hours; Hep3B cells) results in dose-dependent stabilization of nuclear HIF-1[1].TRC160334 (75~300 μM; 4 hours; Hep3B cells) results in dose-dependent transcriptional activation of HIF-1. TRC160334 shows a dose-dependent expression of HIF target genes such as EPO and adrenomedullin[1].

TRC160334 (0.1 and 0.3 mg/kg; i.p.) significantly reduces serum creatinine and blood urea nitrogen[1].TRC160334 (0.3 and 0.6 mg/kg; i.p.) shows reducing trends for acute tubular necrosis[1].TRC160334 significantly reduces the rise in electrolyte excretion dose dependently. Preischemic treatment with TRC160334 results in a pronounced induction of HSP70 in kidneys by 6 hours while postischemic treatment with TRC160334 results in a pronounced induction of HSP70 in kidneys by 12 hours as compared with the respective vehicle control[1].

[1]. Jamadarkhana P, et al. Treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates ischemic acute kidney injury. Am J Nephrol. 2012;36(3):208-218.